Clinical Trial Update: Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 single-dose trial evaluating a new insulin glargine formulation alongside Lantus in Japanese patients with Type 1 Diabetes Mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• New insulin glargine formulation (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED